Vor Biopharma Inc (VOR) Stock Price, Quote & News

Company Profile

Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy. It has a license agreement with RemeGen Co., Ltd. for the exploitation, development, and commercialization of telitacicpet and related...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 655 6580

Website: www.vorbio.com

Address:

500 Boylston Street, Suite 1350, Boston, United States

topstockalerts Jul. 3 at 9:44 PM

$VOR feels stronger than it has any right to be

0 · Reply

focafoca99 Jul. 2 at 9:57 PM

$VOR offering inducement stock options and RSUs to seven new hires under Nasdaq Listing Rule 5635(c)(4).

0 · Reply

pc247cz Jul. 2 at 6:10 PM

$VOR Not selling yet.

0 · Reply

NJgolfer Jul. 2 at 4:16 PM

$VOR weekly OBV/Chaikin MF indicator flipped positive last week and weekly RSI broke out this week. Two positive confirmation signals

0 · Reply

NJgolfer Jul. 2 at 4:14 PM

$VOR weekly buy signal 🚦. First one since June 2025 which resulted in a 200%+ run in two weeks

0 · Reply

STACKD0E Jul. 2 at 3:46 PM

$TENX $CSTE $PALI $RGNX $VOR

0 · Reply

look2hook Jul. 2 at 2:07 PM

$VOR What a stroke of luck. I sold my short premarket. 🫣

1 · Reply

jordonwillusu Jun. 30 at 1:21 PM

$VOR No one here? Target is $30 for me.

0 · Reply

GSP Jun. 30 at 11:23 AM

$ATLN $JACK $VOR $FCEL $WSHP

0 · Reply

GSP Jun. 29 at 11:20 PM

Your Day Trading Watch List for June 30th in About 2 Minutes (con't): $ATLN $JACK $VOR $FCEL $WSHP .

0 · Reply

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

2026-06-08T13:05:34.000Z - 26 days ago

Vor Bio announces China NMPA approval for telitacicept

Jun 8, 2026, 8:31 AM EDT - 26 days ago

Telitacicept Receives NMPA Approval for the Treatment of Sjögren's Disease in China

Jun 8, 2026, 8:30 AM EDT - 26 days ago

Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China

Jun 3, 2026, 9:55 AM EDT - 4 weeks ago

Vor Biopharma Transcript: Jefferies Global Healthcare Conference 2026

May 28, 2026, 8:30 AM EDT - 5 weeks ago

Vor Bio to Participate in the 2026 Jefferies Global Healthcare Conference

2026-05-14T17:08:10.000Z - 7 weeks ago

Vor Bio price target raised to $18 from $15 at Wedbush

May 14, 2026, 8:30 AM EDT - 7 weeks ago

Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicine

May 13, 2026, 8:30 AM EDT - 7 weeks ago

Vor Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 13, 2026, 7:00 AM EDT - 7 weeks ago

Vor Biopharma Quarterly report: Q1 2026

May 13, 2026, 7:00 AM EDT - 7 weeks ago

Vor Biopharma Earnings release: Q1 2026

2026-04-27T20:37:27.000Z - 2 months ago

Vor Bio files to sell 5.34M shares of common stock for holders

Apr 27, 2026, 8:00 AM EDT - 2 months ago

Vor Biopharma Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 2 months ago

Vor Biopharma Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 2 months ago

Vor Biopharma Registration statement: Registration filing

2026-04-15T10:05:49.000Z - 2 months ago

Vor Bio price target lowered to $31 from $32 at H.C. Wainwright

2026-03-31T11:58:58.000Z - 3 months ago

Vor Bio price target raised to $15 from $9 at Wedbush

2026-03-30T18:36:48.000Z - 3 months ago

Vor Bio price target lowered to $40 from $55 at Stifel

2026-03-30T18:30:12.000Z - 3 months ago

Vor Bio price target lowered to $40 from $55 at Stifel

2026-03-30T12:25:44.000Z - 3 months ago

Vor Bio doses first patient in UPSTREAM SjD study

Mar 30, 2026, 8:01 AM EDT - 3 months ago

Vor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Mar 30, 2026, 8:00 AM EDT - 3 months ago

Vor Bio Doses First Patient in Global Phase 3 UPSTREAM SjD Registrational Trial of Telitacicept in Primary Sjögren's Disease

Mar 30, 2026, 7:00 AM EDT - 3 months ago

Vor Biopharma Earnings release: Q4 2025

Mar 30, 2026, 7:00 AM EDT - 3 months ago

Vor Biopharma Annual report: Q4 2025

2026-03-29T23:30:08.000Z - 3 months ago

Vor Bio initiated with a Buy at Jefferies

2026-03-27T12:27:35.000Z - 3 months ago

Vor Bio to sell 5.338M shares at $14.05 in private placement

Mar 27, 2026, 8:00 AM EDT - 3 months ago

Vor Bio Announces $75 Million Private Placement with TCGX

Mar 23, 2026, 4:30 PM EDT - 3 months ago

Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-03-19T10:01:01.000Z - 3 months ago

Vor Bio initiated with an Overweight at Wells Fargo

Mar 6, 2026, 6:00 AM EST - 4 months ago

Vor Biopharma Slides: Corporate presentation

Mar 2, 2026, 9:50 AM EST - 4 months ago

Vor Biopharma Transcript: TD Cowen 46th Annual Health Care Conference

Feb 23, 2026, 8:00 AM EST - 4 months ago

Vor Bio to Participate in the 46th Annual TD Cowen Health Care Conference

Jan 29, 2026, 7:00 AM EST - 5 months ago

Vor Biopharma Registration statement: Registration Filing

Jan 13, 2026, 1:30 PM EST - 6 months ago

Vor Biopharma Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 1:30 PM EST - 6 months ago

Vor Biopharma Slides: 44th Annual J.P. Morgan Healthcare Conference

2026-01-09T11:15:37.000Z - 6 months ago

Vor Bio initiated with a Buy at Citi

Jan 6, 2026, 8:00 AM EST - 6 months ago

Vor Bio to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Dec 23, 2025, 4:01 PM EST - 6 months ago

Vor Bio Appoints RA Capital's Andrew Levin, M.D., Ph.D., and Forbion's Wouter Joustra to Board of Directors

2025-12-23T12:00:24.000Z - 6 months ago

Vor Bio price target lowered to $46 from $64 at Baird

2025-12-19T12:00:56.000Z - 7 months ago

Vor Bio price target lowered to $40 from $43 at JPMorgan

2025-12-17T10:40:21.000Z - 7 months ago

Vor Bio initiated with a Buy at TD Cowen

2025-12-15T13:05:06.000Z - 7 months ago

Vor Bio prices 13.88M shares at $10.81 in private placement

Dec 15, 2025, 8:00 AM EST - 7 months ago

Vor Bio Announces $150 Million Private Placement

2025-12-09T10:00:19.000Z - 7 months ago

Vor Bio initiated with an Overweight at JPMorgan

Dec 2, 2025, 3:00 PM EST - 7 months ago

Vor Biopharma Transcript: Evercore ISI 8th Annual HealthCONx Conference

2025-11-25T13:41:07.000Z - 7 months ago

Vor Bio assumed with a Neutral at Wedbush

Nov 13, 2025, 4:01 PM EST - 8 months ago

Vor Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 13, 2025, 7:00 AM EST - 8 months ago

Vor Biopharma Earnings release: Q3 2025

Nov 13, 2025, 7:00 AM EST - 8 months ago

Vor Biopharma Quarterly report: Q3 2025

Nov 12, 2025, 2:30 PM EST - 8 months ago

Vor Biopharma Transcript: TD Cowen Immunology and Inflammation Summit

Nov 10, 2025, 9:56 PM EST - 8 months ago

Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock

Nov 10, 2025, 4:01 PM EST - 8 months ago

Vor Bio Announces Proposed Public Offering of $100 Million of Common Stock

Nov 10, 2025, 7:00 AM EST - 8 months ago

Vor Biopharma Registration statement: Registration Filing

Nov 8, 2025, 11:45 AM EST - 8 months ago

Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China

Nov 7, 2025, 8:00 AM EST - 8 months ago

Vor Bio to Participate in Upcoming Investor Conferences

Nov 3, 2025, 6:00 PM EST - 8 months ago

Vor Biopharma Slides: Corporate Presentation

Nov 3, 2025, 8:00 AM EST - 8 months ago

Vor Bio Appoints Jeremy Sokolove, M.D. as Chief Medical Officer

Oct 29, 2025, 11:01 AM EDT - 8 months ago

Telitacicept Demonstrates Sustained Efficacy and Favorable Safety Profile in 48-Week China Phase 3 Open-Label Extension Generalized Myasthenia Gravis Data

Oct 28, 2025, 4:30 PM EDT - 8 months ago

Vor Biopharma Transcript: Study Update

Oct 28, 2025, 4:30 PM EDT - 8 months ago

Vor Biopharma Press release: Study Update

Oct 28, 2025, 4:30 PM EDT - 8 months ago

Vor Biopharma Slides: Study Update

Oct 22, 2025, 4:30 PM EDT - 9 months ago

Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjögren's Disease

Oct 17, 2025, 8:00 AM EDT - 9 months ago

Vor Bio Announces Late-Breaking Oral Presentation of China Phase 3 IgA Nephropathy Clinical Study at American Society of Nephrology's Kidney Week 2025

Oct 16, 2025, 8:00 AM EDT - 9 months ago

Vor Bio Announces Publication of China Phase 3 Study of Telitacicept in Systemic Lupus Erythematosus in The New England Journal of Medicine

Oct 14, 2025, 8:00 AM EDT - 9 months ago

Telitacicept Demonstrates Clinically Meaningful and Statistically Significant Impact on ESSDAI Compared to Placebo in Late-Breaking China Phase 3 Results in Primary Sjögren's Disease at ACR 2025

Sep 29, 2025, 7:00 AM EDT - 9 months ago

Vor Bio Announces Late-Breaking Poster Presentation of Phase 3 Primary Sjögren's Disease Clinical Study at ACR Convergence 2025

Sep 24, 2025, 8:00 AM EDT - 10 months ago

Vor Biopharma Registration statement: Registration Filing

Sep 23, 2025, 8:00 AM EDT - 10 months ago

Vor Bio Appoints Navid Z. Khan, Ph.D.

Sep 17, 2025, 9:00 PM EDT - 10 months ago

Results of China Phase III Clinical Study of Telitacicept for Generalized Myasthenia Gravis Selected for Oral Presentation at 2025 AANEM Annual Meeting

Sep 17, 2025, 4:15 PM EDT - 10 months ago

Vor Bio Announces Oral Presentation of 48-Week China Phase 3 Generalized Myasthenia Gravis Clinical Study at AANEM

Sep 15, 2025, 4:00 PM EDT - 10 months ago

Vor Biopharma Transcript: Stifel Virtual Immunology and Inflammation Forum

Sep 12, 2025, 4:15 PM EDT - 10 months ago

Vor Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum

Sep 2, 2025, 11:15 AM EDT - 10 months ago

Vor Biopharma Transcript: Citi's Biopharma Back to School Conference

Sep 2, 2025, 8:00 AM EDT - 10 months ago

Vor Bio Appoints Adi Osovsky, S.J.D. as General Counsel

Aug 27, 2025, 8:00 AM EDT - 11 months ago

Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for IgA Nephropathy

Aug 13, 2025, 8:30 AM EDT - 11 months ago

Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for Primary Sjögren's Disease with Telitacicept, a Dual BAFF/APRIL Inhibitor

Aug 12, 2025, 4:00 PM EDT - 11 months ago

Vor Biopharma Quarterly report: Q2 2025

Aug 8, 2025, 8:00 AM EDT - 11 months ago

Vor Biopharma Proxy statement: Proxy Filing

Aug 4, 2025, 8:30 AM EDT - 11 months ago

Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer

Jul 29, 2025, 8:00 AM EDT - 1 year ago

Vor Biopharma Proxy statement: Proxy Filing

Jul 21, 2025, 8:30 AM EDT - 1 year ago

Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors

Jul 17, 2025, 8:30 AM EDT - 1 year ago

Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer

Jul 10, 2025, 4:00 PM EDT - 1 year ago

Vor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Financial Officer and Chief Business Officer

Jul 1, 2025, 4:00 PM EDT - 1 year ago

Vor Bio Report Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jun 25, 2025, 4:50 PM EDT - 1 year ago

Vor Bio Announces $175 Million Private Placement

Jun 25, 2025, 4:45 PM EDT - 1 year ago

Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset

May 14, 2025, 4:00 PM EDT - 1 year ago

Vor Biopharma Quarterly report: Q1 2025

May 8, 2025, 8:30 AM EDT - 1 year ago

Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Vor Biopharma Proxy statement: Proxy Filing

Apr 8, 2025, 8:00 AM EDT - 1 year ago

Vor Biopharma Proxy statement: Proxy Filing

Apr 8, 2025, 8:00 AM EDT - 1 year ago

Vor Biopharma Proxy statement: Proxy Filing

Mar 28, 2025, 8:00 AM EDT - 1 year ago

Vor Biopharma Proxy statement: Proxy Filing

Mar 20, 2025, 4:05 PM EDT - 1 year ago

Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update

Mar 20, 2025, 8:00 AM EDT - 1 year ago

Vor Biopharma Registration statement: Registration Filing

Mar 19, 2025, 7:00 PM EDT - 1 year ago

Vor Biopharma Earnings release: Q4 2024

Mar 19, 2025, 7:00 PM EDT - 1 year ago

Vor Biopharma Annual report: Q4 2024

Feb 13, 2025, 8:00 AM EST - 1 year ago

Vor Bio Presents Novel Research Highlighting Opportunities and Challenges Facing Institutions Enrolling Patients in Cell and Gene Therapy Trials

Feb 12, 2025, 12:00 PM EST - 1 year ago

Vor Biopharma Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference 2025

Feb 3, 2025, 8:00 AM EST - 1 year ago

Vor Bio to Participate in the Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Jan 21, 2025, 7:00 AM EST - 1 year ago

Vor Biopharma Registration statement: Registration Filing

Jan 8, 2025, 9:00 AM EST - 1 year ago

Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors

Dec 27, 2024, 9:00 AM EST - 1 year ago

Vor Bio Announces $55.6 Million Private Placement

Dec 9, 2024, 8:00 AM EST - 1 year ago

Vor Biopharma Transcript: Status Update

Dec 9, 2024, 8:00 AM EST - 1 year ago

Vor Biopharma Press release: Status Update

Dec 9, 2024, 8:00 AM EST - 1 year ago

Vor Biopharma Slides: Status Update

Dec 9, 2024, 7:30 AM EST - 1 year ago

Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design

Nov 18, 2024, 2:25 PM EST - 1 year ago

Vor Biopharma Transcript: Stifel 2024 Healthcare Conference

Nov 7, 2024, 4:00 PM EST - 1 year ago

Vor Biopharma Earnings release: Q3 2024

Nov 7, 2024, 4:00 PM EST - 1 year ago

Vor Biopharma Quarterly report: Q3 2024

Sep 30, 2024, 7:00 AM EDT - 1 year ago

Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer

Sep 5, 2024, 4:30 PM EDT - 1 year ago

Vor Biopharma Transcript: Study Update

Sep 5, 2024, 4:30 PM EDT - 1 year ago

Vor Biopharma Press release: Study Update

Sep 5, 2024, 4:30 PM EDT - 1 year ago

Vor Biopharma Slides: Study Update

Sep 5, 2024, 4:01 PM EDT - 1 year ago

New Clinical Data Validates Vor Bio's Approach of Using Shielded Transplants to Deliver Targeted Therapies

Aug 8, 2024, 4:05 PM EDT - 2 years ago

Vor Bio Reports Second Quarter 2024 Financial Results and Provides Company Update

topstockalerts Jul. 3 at 9:44 PM

$VOR feels stronger than it has any right to be

0 · Reply

focafoca99 Jul. 2 at 9:57 PM

$VOR offering inducement stock options and RSUs to seven new hires under Nasdaq Listing Rule 5635(c)(4).

0 · Reply

pc247cz Jul. 2 at 6:10 PM

$VOR Not selling yet.

0 · Reply

NJgolfer Jul. 2 at 4:16 PM

$VOR weekly OBV/Chaikin MF indicator flipped positive last week and weekly RSI broke out this week. Two positive confirmation signals

0 · Reply

NJgolfer Jul. 2 at 4:14 PM

$VOR weekly buy signal 🚦. First one since June 2025 which resulted in a 200%+ run in two weeks

0 · Reply

STACKD0E Jul. 2 at 3:46 PM

$TENX $CSTE $PALI $RGNX $VOR

0 · Reply

look2hook Jul. 2 at 2:07 PM

$VOR What a stroke of luck. I sold my short premarket. 🫣

1 · Reply

jordonwillusu Jun. 30 at 1:21 PM

$VOR No one here? Target is $30 for me.

0 · Reply

GSP Jun. 30 at 11:23 AM

$ATLN $JACK $VOR $FCEL $WSHP

0 · Reply

GSP Jun. 29 at 11:20 PM

Your Day Trading Watch List for June 30th in About 2 Minutes (con't): $ATLN $JACK $VOR $FCEL $WSHP .

0 · Reply

Sultanthesultan Jun. 26 at 11:43 AM

$RZLV chatGPT told me $VOR resembles $RZLV when it got deleted : - very high short interest - small cap growth company - sentiment negative - removed after a long decline - had enough cash to continue later experienced a sharp recovery after the forced selling subsided, so I feel it coming.

1 · Reply

focafoca99 Jun. 12 at 8:25 PM

$VOR votes approved an amended equity incentive plan and re-elected two directors at its annual meeting.

0 · Reply

SuperGreenToday Jun. 2 at 2:12 AM

$VOR

0 · Reply

AIBioScanner May. 19 at 3:18 PM

$VOR AI-Based Findings on VOR After running VOR through my AI-driven quantitative framework, the stock is in a downtrend with price falling below both moving averages amid weakening momentum. VOR is trading around $14.13, below both the 20-day (~$15.06) and 50-day (~$14.98) moving averages — indicating continued selling pressure and softening structure. Key signals: • Trading below both MAs — downtrend • MACD negative (-0.05) — bearish momentum • Range between ~$13.81 support and ~$18.05 resistance 1-Month Outlook: Base scenario: consolidation near $12.01–$16.25 Breakout above $16.25 could open a move toward $19.01 Breakdown below $12.01 may extend further downside toward $9.85 Structure is bearish. Requires significant catalyst or volume reversal for recovery. Not financial advice.

0 · Reply

shauntg May. 18 at 9:30 PM

Watching $VOR for a potential squeeze at some point. Free Float 28M. Short approximately 5M shares. Days to cover 4+. While not a strong case for a squeeze, it's worth keeping on a watchlist. Prior pricing was above $50 giving this stock room to run. Potential Catalyst: VOR advanced its Phase 3 telitacicept trial in myasthenia gravis in May 2026, keeping institutional attention elevated. A positive data readout or partnership/licensing deal would be the most credible igniter. Multiple Wall Street desks including JPMorgan (Overweight, $40 PT) and HC Wainwright (Buy) remain bullish, which means there's a sentiment gap between analysts and the short sellers — that tension is exactly what you want on the long side if a catalyst hits.

0 · Reply

theBigDollarski Apr. 30 at 10:25 PM

$VOR looks ripe

0 · Reply

BillionerOfKing Apr. 27 at 5:43 PM

$VOR Current Stock Price: $13.96

0 · Reply

YakoCapital Apr. 27 at 3:51 PM

$VOR

0 · Reply

Multiplyme7x Apr. 25 at 12:28 PM

$XLO this is the same set up at $STRO stayed below $1 for many months then had a reverse split a few months after the split started going up now its above $30 check them out , $VOR and $LYEL also had reverse splits and headed north after a few months of nothing .

0 · Reply

Arcides Apr. 20 at 3:11 PM

$VOR piece of shit...not what you wanna see after a pocket pivot

1 · Reply

RunnerSignals Apr. 15 at 7:45 PM

early signals vs priced moves $TVTX +33% $ZM +7% $VOR -2.8% rsi + volume flagged early. price followed. most traders react late. that gap is where edge exists

1 · Reply

DARKP00L Apr. 15 at 11:09 AM

$VOR 06:51 on Apr. 15 2026 HC Wainwright & Co. Maintains Buy on Vor Biopharma, Lowers Price Target to $31 #tradeideas

0 · Reply

Market Cap	1.12B
Revenue (ttm)	0.00
Net Income (ttm)	-695.98M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	3,911,200
Avg Vol	1,160,828
Day's Range	N/A - N/A
Shares Out	54.19M
Stochastic %K	80%
Beta	1.69
Analysts	Strong Sell
Price Target	$36.14